A clinical review of low-dose naltrexone (LDN) safety for adults aged 50 to 64, covering side effects, drug interactions, dosing, and monitoring considerations for this age group.
A clinician-grade review of low-dose naltrexone (LDN) safety signals, FDA regulatory actions, compounding pharmacy oversight, and adverse-event data from published trials and FAERS reports.
A clinician-level guide to adjusting low-dose naltrexone (LDN) dosing, timing, and monitoring across seasons, covering winter immune shifts, summer heat effects, and condition-specific seasonal flare patterns.
Low-dose naltrexone (LDN) is dispensed as an oral capsule or liquid, not an injectable. Learn how LDN actually works, its mechanism of action via TLR4 and opioid-receptor modulation, and the correct way to take compounded LDN at home.
How to store compounded low-dose naltrexone (LDN), what affects its shelf life, and evidence-based stability data for capsules, liquids, and transdermal formulations.
A guide to switching low-dose naltrexone (LDN) from or to other opioid-antagonist and opioid-agonist medications, covering mechanism, timing risk, washout windows, and compounding considerations, with an emphasis on where evidence is solid and where it is not.
A guide to adjusting compounded low-dose naltrexone (LDN) dosing times during air travel, crossing multiple time zones, and managing circadian disruption without losing therapeutic benefit.
Evidence-based monitoring guide for young adults aged 18-29 taking low-dose naltrexone (LDN). Covers lab schedules, liver function, fertility considerations, and when to adjust dosing.
A guide to how low-dose naltrexone (LDN) affects appetite, food cravings, and body weight, with primary-literature citations, dosing context, and practical guidance.
Compare compounded low-dose naltrexone with FDA-approved 50 mg naltrexone tablets and extended-release injection, including evidence limits, formulation differences, opioid interactions, and questions to ask a prescriber or pharmacy.
A clinical review of emerging LDN delivery systems, novel formulations in development, ongoing trials, and the regulatory path toward FDA-approved low-dose naltrexone products.
A clinical history of low-dose naltrexone (LDN) from its 1984 FDA approval as an opioid antagonist through off-label adoption for fibromyalgia, autoimmune disease, and chronic inflammation.
A guide to discontinuing low-dose naltrexone (LDN) safely, including tapering schedules, rebound risk, mechanism of action, and what clinical evidence actually shows.
A clinician-level guide to safely restarting compounded low-dose naltrexone (LDN) after an acute illness, including when to pause, how to re-titrate, and what the evidence says about opioid receptor modulation and immune function.
Your first month of low-dose naltrexone: weekly symptom tracking, sleep and side effects, prescription checks and the month-one treatment review.
Naltrexone can trigger acute opioid withdrawal at any dose, including 1.5mg LDN. See which opioids, medications, and supplements to avoid.